Reading the annual reports…

First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.

Astrazeneca PLC financial health, profit and balance sheet · Scorvest

Sweden

Astrazeneca PLC

Fiscal year ends in December · Figures in USD

+ Add to watchlist Compare

In shortAstrazeneca PLC is profitable, generates cash and carries moderate debt, with revenue growing (+8.6% last year).

Financial health

Strong

Built from five areas over the last five annual reports. Tap an area to see the figures behind it.

How is this score calculated? →

Profitability96

Operating marginShare of each sale left after running the business, before interest and tax.	23.4%	95/100
Net marginShare of each sale left as profit after every cost, interest and tax.	17.4%	90/100
Return on equityProfit earned on the money shareholders put in. Above 15% is strong.	22.9%	100/100
Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge.	14.8%	99/100

Weight in the score: 25%

Balance sheet48

Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash.	0.94×	12/100
Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted.	0.57×	79/100
Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable.	1.61×	68/100
Interest coverageHow many times operating profit covers interest. Below 2 is risky.	8.11×	63/100
Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress.	1.80	18/100

Weight in the score: 25%

Cash generation100

Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt.	20.0%	100/100
Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy.	1.15×	100/100
Years with positive free cash flow (last 5)	5 of 5	100/100

Weight in the score: 20%

Stability73
Profitable years (last 5) 5 of 5 100/100
Years of revenue decline (last 5) 0 of 5 100/100
Revenue growth volatility 14.3% 58/100
Operating margin volatility 8.4% 33/100
Weight in the score: 20%
Growth86
Revenue growth, 3-year average 9.8% 71/100
EPS growth, 3-year average 45.8% 100/100
Weight in the score: 10%

Profitable years (last 5)	5 of 5	100/100
Years of revenue decline (last 5)	0 of 5	100/100
Revenue growth volatility	14.3%	58/100
Operating margin volatility	8.4%	33/100

Revenue growth, 3-year average	9.8%	71/100
EPS growth, 3-year average	45.8%	100/100

Fiscal year 2025 · change vs prior year

Revenue: $58.7B; ▲ 8.6%
Net income: $10.2B; ▲ 45.3%
Free cash flow: $11.8B; ▲ 18.4%
Operating margin: 23.4%; +4.9 pts
Cash & investments: $5.7B; –
Total debt: $27.8B; ▼ 3.6%
Diluted EPS: $6.54; ▲ 45.3%
Return on equity: 22.9%; –

European data comes from annual reports in ESEF format (since 2020). Industry and ticker are not provided by this source.

Trends

Annual figures as reported. Hover a bar or point for the exact value.

2 older years available with the 10-year history. Essential plan, from €8.25/month →

Revenue and net income

RevenueNet income

Margins

Statements

The last 5 fiscal years from the company's annual reports.

USD millions; negative values in parentheses.

Fiscal year	FY21	FY22	FY23	FY24	FY25
Revenue	37,417	44,351	45,811	54,073	58,739
Cost of revenue	12,437	12,391	8,268	10,207	10,633
Gross profit	24,980	31,960	37,543	43,866	48,106
Research & development	9,736	9,762	10,935	13,583	14,232
Selling, general & admin	15,234	18,419	19,216	19,977	19,933
Operating income	1,056	3,757	8,193	10,003	13,743
Interest expense	1,300	1,346	1,626	1,742	1,694
Pre-tax income	(265)	2,501	6,899	8,691	12,402
Income tax	(380)	(792)	938	1,650	2,169
Net income	112	3,288	5,955	7,035	10,225
Diluted EPS	$0.08	$2.11	$3.81	$4.50	$6.54
Diluted shares (millions)	1,427	1,560	1,562	1,563	1,562

2 older years available with the 10-year history. Essential plan, from €8.25/month →

Risk checks

Altman Z'' score

1.80 Grey zone

Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.

Piotroski F-score

8/9

Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.

Positive net income: passed
Positive operating cash flow: passed
Return on assets improved: passed
Cash flow exceeds net income: passed
Long-term debt ratio fell: passed
Current ratio improved: passed
No share dilution: passed
Gross margin improved: passed
Asset turnover improved: failed

Sources

Annual reportPeriod ending Dec 31, 2025Open the report ↗
Annual reportPeriod ending Dec 31, 2024Open the report ↗
Annual reportPeriod ending Dec 31, 2023Open the report ↗
Annual reportPeriod ending Dec 31, 2022Open the report ↗
Annual reportPeriod ending Dec 31, 2021Open the report ↗

All figures: filings.xbrl.org (ESEF). Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works

Latest annual report: Dec 31, 2025 · Data updated Dec 31, 2025